Emergent BioSolutions Management
Management criteria checks 2/4
Emergent BioSolutions' CEO is Joe Papa, appointed in Feb 2024, has a tenure of 1.08 years. directly owns 0.52% of the company’s shares, worth $1.61M. The average tenure of the management team and the board of directors is 2 years and 3.7 years respectively.
Key information
Joe Papa
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load?
Mar 05
There's No Escaping Emergent BioSolutions Inc.'s (NYSE:EBS) Muted Revenues Despite A 26% Share Price Rise
Jan 22Emergent BioSolutions: Stock Is A Likely Winner In 2025
Jan 14Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth
Nov 09Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
Nov 08Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Oct 28Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario
Oct 04Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding
Sep 16Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval
Aug 18Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%
Aug 02Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process
Jul 15Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround
May 10New CEO Appointment A Clear Positive For Emergent BioSolutions
Feb 27Emergent BioSolutions: Q3 Numbers Leave Work To Be Done
Dec 18Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow
Nov 23Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
Aug 23Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)
Aug 14Emergent BioSolutions: Making A Big Bet On Narcan
Jul 21An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued
Jun 22Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?
Apr 05Emergent Biosolutions Q4 2022 Earnings Preview
Feb 24CEO
Joe Papa (68 yo)
1.1yrs
Tenure
Mr. Joseph C. Papa, Jr. also known as Joe, is Independent Non-Executive Director of Milestone Pharmaceuticals Inc. since September 3, 2024. Mr. Papa serves as Executive Advisor at Water Street Healthcare P...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP | 7yrs | US$2.18m | 0.55% $ 1.7m | |
| Chief Quality & Compliance Officer | 2.9yrs | US$1.68m | 0.33% $ 1.0m | |
| Senior Vice President of Products Business | 2.2yrs | US$1.06m | 0.16% $ 491.3k | |
| CEO, President & Director | 1.1yrs | no data | 0.52% $ 1.6m | |
| Senior VP | 1.2yrs | no data | 0.13% $ 389.1k | |
| Senior VP & Chief Human Resource Officer | 2yrs | no data | no data | |
| Senior VP | 2yrs | no data | no data | |
| Senior Vice President of Manufacturing & Bioservices | no data | no data | 0.20% $ 625.7k | |
| Chief Medical Officer & Head of Research and Development | less than a year | no data | no data |
2.0yrs
Average Tenure
58.5yo
Average Age
Experienced Management: EBS's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.1yrs | no data | 0.52% $ 1.6m | |
| Independent Director | 18.8yrs | US$400.23k | 0.098% $ 304.0k | |
| Independent Director | 20.2yrs | US$394.73k | 0.037% $ 112.9k | |
| Independent Director | 1.4yrs | US$397.50k | 0.027% $ 82.8k | |
| Independent Director | 2.9yrs | US$396.99k | 0.011% $ 32.6k | |
| Independent Director | 4.4yrs | US$405.98k | 0.067% $ 208.6k | |
| Independent Non-Executive Chairman | 20.6yrs | US$535.98k | 0.070% $ 216.5k | |
| Independent Director | 8.4yrs | US$413.48k | 0.050% $ 153.9k | |
| Independent Director | 1.4yrs | US$398.75k | 0.19% $ 575.3k | |
| Independent Director | 2.7yrs | US$382.23k | 0.0073% $ 22.5k |
3.7yrs
Average Tenure
65yo
Average Age
Experienced Board: EBS's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/19 21:54 |
| End of Day Share Price | 2025/03/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Emergent BioSolutions Inc. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Robert Wasserman | Benchmark Company |
| Mario Corso | Caris & Company |